Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
very soon, very stable developments
Wow, great article, thank you Blockchain!
YES LOOKS GOOD
CHECK ABOUT THE TEAM:
EXPERT LEADERSHIP
The principals, directors and advisors of Lexington
BioSciences have been individually and collectively
involved in raising extensive capital funding for their
private and public companies. Team members have held
numerous executive leadership positions encompassing
biotechnology, and medical device companies, as well as
multi-national corporations. The team includes inventors,
scientists, and business people who have successfully
started, built and grown multiple life science companies.
Find out more at:
www.lexingtonbiosciences.com/company/management
About Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium - the vital innermost lining of a person's cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. By taking delivery of the clinical trial ready HeartSentry units the company will commence studies as soon as possible. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit:
https://lexingtonbiosciences.com/.
Eric Willis
CEO & Director
LXGTF on green again and ok volume
yes is good to know all the story
strange moves but .50 surely expected
The FACTS ARE: Undiagnosed Cardiovascular Disease Is a Killer
• 1 in 3 deaths annually are caused by heart disease
and stroke.
• 1.5 million people suffer heart attacks annually in
the U.S.
• Nearly 1/3 of the deaths could be prevented
through proactive changes in lifestyle habits.
• Often the FIRST SYMPTOM of coronary artery
disease is a heart attack.
LXGTF running again!
agreed!
yes going strong
Looks like that yes
yes I am exited about this!
Great annual average, impressive!
Good morning !!!
LXGTF is STEPs BEFORE OTHERS! Endothelial function measurement predicts when arteries are vulnerable to developing atherosclerosis
LXGTF REAL ADVANTAGE! Current Standards are Complicated and Expensive
• Gold standard - ULTRASOUND
• Measurement directly views arterial diameter
changes
• Only at specialized diagnostic centers
• Requires trained ultrasonographer
• Expensive capital equipment needed
• Alternative method - ENDOPAT
• Measurement uses a fingertip blood oxygen
sensor and laptop computer.
• Only at specialized diagnostic centers
• Requires trained technician
Currently only used in specialized research centers by highly trained staff
Yes Mike, good morning!
the video is really WORTHY!!!
always good to remember, thank you Italian
Happy for a new week!
Good morning all! :)
OK that's cool
WOW, STEP BEFORE OTHERS! Endothelial function measurement predicts when arteries are vulnerable to developing atherosclerosis
...we need a simple way to proactively measure and monitor
cardiovascular system health BEFORE the development of heart disease
The FACTS ARE: Undiagnosed Cardiovascular Disease Is a Killer
• 1 in 3 deaths annually are caused by heart disease
and stroke.
• 1.5 million people suffer heart attacks annually in
the U.S.
• Nearly 1/3 of the deaths could be prevented
through proactive changes in lifestyle habits.
• Often the FIRST SYMPTOM of coronary artery
disease is a heart attack.
Morning SPac, thenk you for info
WOW up and green, let's go LXGTF!
where I can find more info about that?
LXGTF save lifes and IS BETTER THEN OTHERS! Current Standards are Complicated and Expensive
• Gold standard - ULTRASOUND
• Measurement directly views arterial diameter
changes
• Only at specialized diagnostic centers
• Requires trained ultrasonographer
• Expensive capital equipment needed
• Alternative method - ENDOPAT
• Measurement uses a fingertip blood oxygen
sensor and laptop computer.
• Only at specialized diagnostic centers
• Requires trained technician
Currently only used in specialized research centers by highly trained staff
BEFORE OTHERS! Endothelial function measurement predicts when arteries are vulnerable to developing atherosclerosis
I LIKE THIS: Knowing the core health of the cardiovascular system is critical to preventing future heart attacks and strokes
• Monitoring cardiovascular health changes over time is key to prevention via lifestyle modification, physician care and ongoing monitoring.
• Traditional measures of blood pressure and cholesterol measurements are only partial indicators of cardiovascular health.
Morning Mike, yes me too
Good morning everybody, hope you enjoyed thanksgiving!
today we have shorter time, let see
Good morning dear friends, hope you had a great thanksgiving day!
guys have a great holiday, see you soon, friday is working day right?
500% is impressive sensitivity